named programs · 4 · from sources
What they call their work
Continuing Medical Education (CME/CE)
Accredited educational programs offering continuing education credits to healthcare professionals based on Medical Letter content
Drugs of Choice Handbooks
Reference guides summarizing evidence-based drug recommendations for various medical conditions
Institutional Site Licenses
Subscription service providing access to Medical Letter publications for hospitals, universities, and healthcare organizations
The Medical Letter on Drugs and Therapeutics
Biweekly newsletter providing critical appraisals of new prescription drugs and comparative reviews of treatments for common diseases
activities · 3 groups
What they do
-
Medical Research & Education Dissemination 2 activities
- Distribution of Drugs of Choice HandbooksPublishes and distributes the Drugs of Choice Handbooks, which summarize evidence-based drug recommendations for clinicians, supporting treatment decision-making in primary care and specialty practice.
- Publication of evidence-based drug reviewsProduces and distributes a biweekly publication, The Medical Letter on Drugs and Therapeutics, that provides peer-reviewed, evidence-based appraisals of new and previously approved prescription drugs, including comparative reviews of treatments for common diseases based on efficacy, safety, adverse effects, drug interactions, and cost. The print version is published 26 times per year and distributed by mail to subscribers.
-
-
Medical Professional Education & Training 1 activity
- Provision of continuing medical education (CME/CE) programsOffers free continuing medical education (CME) and continuing education (CE) credits with each issue of The Medical Letter, allowing healthcare professionals to earn up to 52 credits annually, including credits applicable to ABIM MOC and ABS Continuing Certification.
-
-
Uncategorized 2 activities
- Online access to publication archivesProvides online access to a complete archive of The Medical Letter issues from 1988 to the present, enabling subscribers to search and retrieve historical drug evaluations and clinical reviews.
- Reporting on specific drug approvals and safety issuesPublishes detailed reports on recent FDA drug approvals, safety warnings, and postmarketing adverse event data, such as coverage of ensitrelvir for COVID-19 prophylaxis, orlistat-related kidney injury risks, bemotrizinol in sunscreens, icotrokinra for psoriasis, insulin icodec, olezarsen for hypertriglyceridemia, and difamilast for atopic dermatitis.
-
financials · form 990 · fy2024
revenue
Total revenue$4.31M
Contributions & grants$00%
Program service revenue$3.98M92%
Investment income$164K4%
Other revenue$164K
expenses
Total expenses$3.90M
Program expenses86%
Admin / overhead14%
Fundraising0%
Salaries & benefits$2.65M
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$4.38M
Cash$3.37M
Investments$0
Liabilities$2.73M
Net assets$1.66M
Liquid reserves10.4 mo
6 years on record · 2019–2024 · YoY revenue -3.8%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 9
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| MARK ABRAMOWICZ MD | PRESIDENT | 40 | $320K |
| JEAN-MARIE PFLOMM | EDITOR IN CHIEF | 40 | $290K |
| JOANNE VALENTINO | EXEC. DIR. - MARKETING & C | 40 | $176K |
| SUSIE WONG | EDITOR | 40 | $156K |
| MICHAEL VISCUSI | EDITOR | 40 | $154K |
| SUSAN DARON | EDITOR | 40 | $137K |
| CORINNE MORRISON | EDITOR | 40 | $135K |
| ELAINE REANEY-TOMASELLI | SITE LICENSE SALESPERSON | 40 | $134K |
| AMY FAUCARD | EDITOR | 40 | $131K |
board members · 3
- HOWARD PRESANT — DIRECTOR
- STEPHEN BAUM — DIRECTOR - CHAIRMAN
- WILLIAM FRISHMAN MD — DIRECTOR
relationships · 8
Who they work with
- ABIM Government — Provides MOC points for ABIM through CME/CE credits
- ABS Government — Provides Continuing Certification points for ABS through CME/CE credits
- Consumers Union Network — co-founded by Arthur Kallet, co-founder of Consumers Union, and Dr. Harold Aaron, who served on its advisory board
- FDA Government — References FDA drug safety communications and labeling changes for orlistat (Alli).
- Janssen Partner — Referenced in connection with the drug icotrokinra (Icotyde) for psoriasis.
- Otsuka Partner — Referenced in connection with sibeprenlimab (Voyxact), indicating collaboration or information sharing in drug evaluation.
- Shionogi Partner — Referenced Shionogi as the manufacturer of ensitrelvir (Xocova) in a drug evaluation article.
- Taiho Oncology Partner — Manufacturer of Inqovi, referenced in the context of FDA approval and drug evaluation.
strategies · 1
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Evidence-Based Drug Review via Independent Expert Consensusmethodology: evidence_based_reviewBy conducting independent, evidence-based reviews of pharmaceuticals through a consensus process of medical experts, we produce reliable and unbiased drug evaluations that support clinical decision-making, because independence from industry funding and reliance on scientific rigor ensures objectivity and trustworthiness.